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Abstract 
Tuberculosis is an infectious disease, affecting mostly lungs, that is still considered a health 
global problem as it causes millions of deaths worldwide. Current treatment is effective, 
however, associated with severe adverse effects due to the high doses of each anti-
tuberculosis drug daily administrated by oral therapy. For the first time, a pyrazinoic acid 
biodegradable nanoconjugate was synthesized and developed for pulmonary administration in 
an attempt to reduce the administered doses by achieving a high drug payload and controlled 
release at the target site. The conjugate was synthesized by coupling pyrazinoic acid on 
carboxylic groups of poly(malic acid), which is a biodegradable and biocompatible polymer, 
and posteriorly self-assembled into nanoconjugates. Characterization confirmed the formation 
of nanometric, spherical and negatively charged pyrazinoic acid nanoconjugate (NC-PA). 
NC-PA was stable for 60 days at 4 and 37 ºC and able to deliver PA in a sustained release 
manner over time. On macrophages, they exhibited no cell toxicity for a wide range of 
concentrations (from 1 to 100 µg/mL), demonstrating the safety of NC-PA. In addition, the 
nanoconjugate was efficiently taken up by RAW 264.7 cells over 6 hours reaching a 
maximum value after 3h of incubation. In conclusion, innovative nanoconjugates are a 
promising alternative to deliver drugs directly to the lungs and contributing to improving 
tuberculosis therapy. 
Keywords: nanoconjugate, pyrazinoic acid, poly(malic acid), tuberculosis. 
Rationale and purpose 
Tubercolisis treatment remains a significant clinical challenge. It’s still necessary to improve 
bioavailability and reduce the administration frequency of anti-tubersolisis drugs. A 
promising approach consists to develop a nanomedicine out of a poly (malic acid) conjugate 
with a high drug loading rate and a controlled release process avoiding commonly observed 
drug leakage. The process was applied to an anti-tuberculosis drug: pyrazinoic acid providing 
low toxicity and high intracellular penetration in order to target intracellular bacteria. 
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Introduction 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, a pathogen 
that resides partially within alveolar macrophages[1]. TB is considered worldwide as one of 
the leading causes of death produced by a single infectious agent. It is regarded by many 
countries as public health and social concerns[2]. The World Health Organization (WHO) 
recommends a treatment guideline that comprises the association of four anti-tuberculosis 
drugs within a minimum six-month period[2]. However, daily high doses of each drug 
required for an effective patient response are associated with the occurrence of systemic and 
severe adverse effects, mostly hepatotoxicity, affecting consequently patient compliance[3], 
[4]. Failed therapy contributes to the emergence of bacteria multidrug-resistant TB that 
additionally demands the introduction of second-line anti-tuberculosis drugs into the 
therapeutic regimen, elongating the period of treatment and culminating in side-effects much 
more toxic[5]. 
Pyrazinamide (PZA) is one of the four first-line anti-tuberculosis drugs used in the standard 
protocol of TB treatment. Since PZA was introduced, TB therapy was shortened from 12 to 6 
months, due to its specific ability to act against non-growing tubercle bacilli resident inside 
the acidic pH of phagosome that cannot be killed by other anti-tuberculosis drugs[6],[7]. 
When combined with rifampicin or isoniazid, PZA exhibits unique sterilizing and synergistic 
effects making this drug essential for a successful treatment. The PZA mechanism of action is 
still unknown, however, Zhang and co-workers[6]. Produced the hypothesis that PZA is a 
prodrug that enters the bacilli, and is converted into its active moiety, the pyrazinoic acid 
(PA), through the action of the mycobacterial enzyme pyrazinamidase. Although PA is known 
as the active PZA metabolite, the use of this drug alone is not recommended, because of its 
poor lipophilicity and high-ionized state at physiological pH that limit its diffusion and 
passage through the bacilli cell wall, leading to the drug low bioavailability[8], [9]. Recently, 
the synthesis of alternative pyrazinoic acid prodrugs which do not require bioactivation by an 
enzyme arose as a smart strategy for overcoming the above limitations. Cynamon et al.[10] 
have proposed novel PA esters with better anti-mycobacterial activity than PZA itself; the 
same encouraging result with the additional finding of an improved drug stability in serum 
was demonstrated by Simões et al[11] after evaluating conjugates of PA esters and amide 
derivatives, reinforcing the potential of these ester products to be more effective than PZA 
against mycobacteria.  
4 
 
Direct administration of anti-tuberculosis drugs to the lungs offers major advantages over 
traditional oral therapy[12]–[14]. First, the pulmonary route allows delivering drugs directly 
on TB target site - the alveolar macrophages. Then, local delivery can achieve a high drug 
concentration at the site of infection with the intention of improving therapeutic effect and 
reducing systemic exposure. Sung et al.[15] corroborated this hypothesis by developing a dry 
powder composed of rifampicin porous-nanoparticle aggregate particle (PNAP) and 
performing a pharmacokinetic study in vivo. Formulations administered by intratracheal 
insufflation were effective in maintaining rifampicin amounts in the lungs over a longer 
period of 8 hours, whereas after oral or intravenous delivery, no more rifampicin was 
detected. Interestingly, the same pulmonary route was tested for the administration of an 
aerosol without nanoparticle formulation and rifampicin was not detected in the lungs after 8 
hours, emphasizing the advantageous strategy of delivering nanoparticles via the pulmonary 
route.  
Numerous studies on the design of nanoparticle-based anti-TB drugs over the past decade 
report their potential to improve drug bioavailability and reduce drug dosing frequency[14], 
[16]–[18]. However, despite promising results, physical loading of anti-TB drugs in 
nanoparticles was characterized by a poor loading efficiency and a burst release. As an 
alternative strategy, in this work, drug-polymer conjugation has been considered to improve 
the absorption and bioavailability of anti-tuberculosis-type medications. Compared to 
conventional nanoparticles, nanoconjugates reveal attractive properties such as high-loading 
capacity and sustained release without drug leakage among others[19], [20]. After 
administration, these nanoconjugates can be easily degraded through an enzymatic or 
hydrolytic mechanism, releasing the active molecule directly on the target site.  
In the field of drug delivery systems, several (bio)degradable polymers have been studied to 
formulate polymer-drug conjugates. Among them, poly(malic acid) (PMA), an aliphatic 
polyester, has been proven to be a promising candidate[21]. In addition to these excellent 
degradation and biocompatibility properties, presence of carboxyl group on each repeating 
unit allows for chemical modification with a large spectrum of therapeutic molecules. It has 
been extensively investigated as a water-soluble, biodegradable, and biocompatible polymer, 
with remarkable advantages in clinical use[22]. 
The nanoconjugate, we designed, is based on poly(malic acid), a water-soluble polyester. PA 
was chemically conjugated to the polyester backbone via a hydrolyzable carboxylic acid ester 
linker. To improve the stability and afford self-assembly of the conjugate system, a 
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hydrophobic spacer was introduced between the polymer and the drug. After synthesis, the 
self-assembly behavior was studied and characterized and in vitro release was investigated. 
Cytotoxicity and nanoconjugate cell-uptake were evaluated on macrophages, the cell target. 
 
Materials and Methods 
For synthesis experiments, all solvents were of analytical or HPLC grade. L-malic acid, N,N – 
dicyclohexylcarbodiimide (DCC) and 4-dimethyl aminopyridine (DMAP) were purchased 
from Sigma-Aldrich (France). Pyrazinoic acid (PA) and 1,8-octanediol were provided by TCI 
(Europe, N.V.). Rhodamin B-PLGA was supplied from PolySciTech (USA). All reagents 
were used as received. For cell culture experiments, Dulbecco’s Modified Eagle Medium 
(DMEM), 3-[4,5-dimethylthiazol-2-yl]-3,5 diphenyl tetrazolium bromide (MTT), penicillin, 
streptomycin, and phosphate buffered saline (PBS) were purchased from Sigma-Aldrich 
(France). Fetal bovine serum (FBS) was obtained from Thermo Fischer Scientific (USA).  
Experiments 
Synthesis of PMA 
PMA was obtained by polycondensation of L-malic acid[23]. 5 g of L-malic acid (37 mmol) 
was added into a schlenk flask and heated at 110 ºC during 72h under 0.7-1 mmHg. The 
viscous product was dissolved in tetrahydrofuran (THF) and purified twice by precipitation 
into a diethyl ether:petroleum ether (60:40). The precipitated polymer was dissolved in 
purified water and freeze-dried for 24h (Alpha 2-4 LD Plus, Christ). L-malic conversion = 
76% (
1
H NMR). 
Synthesis of PA conjugates 
PA conjugate was obtained by esterification reactions, performed in two steps. 
Step 1: Synthesis of intermediate PA:Oct product. 2 g of PA (16.1 mmol) and 2.3 g of 1,8-
octanediol (16.1 mmol) were dissolved in 80 ml of anhydrous THF. In another round bottom 
flask, 2.5 g of DCC (12.1 mmol) and 0.2 g of DMAP (1.6 mmol) were dissolved in 40 ml of 
anhydrous THF. After complete dissolution, DCC:DMAP solution was added dropwise into 
the PA:1,8-octanediol solution and the reaction went over overnight at room temperature. The 
reaction mixture was filtered and the solvent was evaporated. The crude product was purified 
by column chromatography, using ethyl acetate as eluent. Yield = 50%. 
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Step 2: Synthesis of PA conjugate. In a round bottom flask, 614 mg of PMA and 466 mg of 
PA:Oct (molar ratio: nMA unit = 2.9 nPA:Oct) were added and dissolved in 20 ml of anhydrous 
THF. In another flask, 572 mg of DCC (2.78 mmol) and 64.5 mg of DMAP (0.53 mmol) were 
dissolved in 20 ml of anhydrous THF. Both solutions were maintained under argon flow and 
magnetic stirring. After complete dissolution, the DCC:DMAP solution was added dropwise 
to the PMA-OctPA solution, at 0 °C for 30 min. The reaction was carried overnight at room 
temperature, then filtered and the product was condensed by solvent evaporation. The crude 
product was dissolved in chloroform and purified twice by precipitation into a diethyl 
ether:petroleum ether solution (60:40). PMA:OctPA was dried under vacuum and recovered 
as a slightly brown powder. 
PMA and conjugate characterization 
1
H NMR spectroscopy was performed in 5 mm diameter tubes in CDCl3 on a Bruker 
Avance-300 (300 MHz) spectrometer. Intermediate product from PA conjugate synthesis 
(PA:Oct) was characterized by electrospray ionization mass spectrometry (LTQ- Velos Pro 
Thermofisher Scientific). 
The molar mass and dispersity of polymers were measured by size-exclusion 
chromatography (SEC). Measurements were performed at 30°C with two columns from 
Malvern Panalytical (Viscotek LT4000L Mixed, Low 300 x 8 mm), a triple detection system 
(Viscotek 270 Dual Detector and Waters 2414 Refractive Index Detector) coupled with a 
Waters 515 HPLC pump and Waters 717plus Autosampler. THF was used as the eluent with a 
flow rate of 1 mL/min. 
Preparation of PA-nanoconjugate 
The labeled NC-PA was obtained by the nanoprecipitation method, which is based on 
nanoparticle formation through rapid diffusion of the solvent into the aqueous phase[24]. 
Briefly, 5 mg of PMA:OctPA was dissolved in 0.5 ml of THF. This organic phase was placed 
into a syringe-pump apparatus and then slowly added to an aqueous phase, composed of 5 ml 
of purified water, at a constant rate of 7 ml/min and under moderate magnetic stirring. The 
solvent was evaporated, yielding nanoparticles at 1.0 mg/ml. In addition, fluorescent 
nanoparticles labeled with Rhodamin B-PLGA were also prepared following the same 
procedure and replacing the total amount of conjugate to a mixture of 5% of Rhodamin B-
PLGA and 95% (w/w) of PMA:OctPA, labeled NC-PAFLU. 
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Nanoconjugate characterization 
Particle size and zeta potential analysis 
NC-PA was characterized by means of particle size and polydispersity index (PDI) 
through dynamic light scattering technique and zeta potential by electrophoretic mobility. For 
size distribution measurements, each sample was diluted in purified water (1:10 ratio), while 
for surface charge measurements, the same dilution ratio was performed in a 1 mM NaCl 
solution. Analyses were carried out in triplicate on three different batches at 20 ºC, using a 
Zetasizer Nano Zs (Malvern Instruments, UK). 
Transmission electron microscopy (TEM) 
Morphology of NC-PA was analyzed by TEM images. 5 µl of nanoconjugate was 
deposited onto copper grids covered with a formvar film (400 mesh) for 2 min. Then, NC-PA 
were covered with 5 µl of a 0.5% (w/v) uranyl acetate solution, for 30 s. Colorant excess was 
removed with a filter paper and samples were observed in a JEOL JEM-1400 microscope 
operating at 80 kV with a filament current of about 55 µA, a post-column high-resolution (11 
megapixels) and a high-speed camera (SC1000 Orius; Gatan). Data were acquired from 
Digital Micrograph (Gatan). 
Stability tests 
NC-PA was stored at refrigerated (4 ºC) and physiological (37 ± 2ºC) conditions for 
60 days. Periodically, a sample was collected and evaluated as particle size and PDI. Analyses 
were done in triplicate on three different batches at 20 ºC. 
In vitro drug release 
2 ml of NC-PA at 1.0 mg/ml were separately dispersed into 8 ml of PBS (pH 7.4). 
Then, aliquots of 0.5 ml were stored into vials, incubated at 37 ºC under shaking and 
protected from light. During a period of 5 days, at each 12 h, a sample from each 
nanoconjugate was collected and frozen. At the end of the experience, samples were unfrozen 
and the amounts of PA released at each time point were quantified by an HPLC method 
described below. Free PA solutions were also prepared in the same conditions and analyzed 
using the same procedure to follow the potential degradation of the drug. 
HPLC system 
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HPLC was employed to quantify PA amounts. The system was composed of a Waters 
1525 Binary HPLC Pump, an injector Waters 2707 Autosampler and an UV-visible Waters 
2998 Photodiode Array Detector. Data acquisition was done using the Empower software. PA 
was assessed following the protocol described by Simões et al[11]. An RP18 Hydro (250 mm 
x 4.6 mm x 5.0 µm, Phenomenex) column was used at a temperature of 35 ºC. The eluent was 
composed of a mixture of acetonitrile and 25 mM phosphate buffer (pH 2.0 adjusted with 
phosphoric acid) in a proportion of 5:95% (v/v). The isocratic flow rate was 1.0 ml/min and 
UV detection was set at λ = 267 nm. PA retention time was 5.47 min. Values reported on each 
time point analysis were plotted on a PA calibration curve (5 – 200 µg/ml) and quantified 
following the equation y = 65936x – 92640 (R² = 0.9999). 
Cell culture assays 
Cell culture 
Murine alveolar macrophages – RAW 264.7 cells (ATCC® TIB-71™) were cultured 
in DMEM supplemented with 10% FBS, 50 U/ml penicillin and 50 U/ml streptomycin. Cells 
were incubated at 37 ºC in a 5% CO2 humidified atmosphere and passaged twice a week at a 
1:10 ratio. 
Cytotoxicity 
Cytotoxicity of nanoconjugate was evaluated using the MTT test, as previously 
described by Mosmann[25]. Cells were seeded at a density of 4000 cells per well in 96-well 
plates and pre-incubated for 24 h. Culture medium was discarded and cells were treated with a 
different range of nanoconjugate concentration diluted in fresh medium. PA and pure PA 
were incubated at 1, 5, 10, 25, 50 and 100 µg/ml with cell culture. Untreated cells were used 
as control. Plates were incubated for 48 h and then 20 µl of a 5 mg/ml MTT solution was 
added in each well for more 2 h to enable crystals formation. Culture medium was removed 
and 200 µl of DMSO was added to dissolve formazan crystals. Plates were shaken for 10 
minutes at room temperature (20 ± 2 ºC) and the absorbance was measured at 540 nm in a 
microplate reader. Cell viability, expressed as a percentage, was calculated as the absorbance 
ratio of treated cells to untreated cells (control). The IC50, expressed as the concentration 
required by each treatment to induce cell death of 50%, was calculated using a sigmoidal 
regression and GraphPad Prism 6 software (USA). 
Nanoconjugate cellular uptake 
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The kinetics of nanoconjugate internalization by RAW 264.7 macrophages was 
investigated by confocal microscopy, following an adapted protocol described by Grabowski 
et al[26]. Briefly, cells were seeded at a density of 80000 cells per well in 6-well plates, 
containing a glass coverslip in each well. 24h after incubation at 37 ºC in a 5% CO2 
humidified atmosphere, non-adherent cells were washed off and all other cells were treated 
with fluorescent-labeled PA nanoconjugate (NC-PAFLU) at 10 µg/ml diluted in a fresh 
culture medium. Untreated macrophages were used as control. Cells were re-incubated at the 
same conditions and, at pre-determined intervals (0.5, 1.5, 3 and 6h), they were assessed with 
an LSM 510 (Zeiss-Meta) confocal microscope equipped with Argon (488 nm, 300 mW) and 
Helium-Neon (543 nm, 5 mW) lasers, and a plan-apochromat 63x objective. Data were 
acquired from LSM 510 software, version 3.2. In addition, for each pre-determined time 
evaluated on a microscope, an average of 20 cells was selected and fluorescence was 
quantified inside them, using ImageJ software. 
Statistical analysis 
Statistical analysis data are presented as mean values with standard deviation (SD). 
Statistical analysis was performed with the Prism Graph-Pad 7.0 software and the significance 
was calculated using a one-way ANOVA method, in which p < 0.05 was considered 
statistically significant (*p < 0.05, **p < 0.005, *** p < 0.0005, **** p < 0.0001). 
Results and Discussion 
Conjugate synthesis and characterization 
In this study, it was important to make a judicious choice of the degradable polymer 
backbone to allow the self-assembly and loading capacity of nanoconjugates. Poly(malic acid) 
(PMA) has been extensively investigated as a water-soluble, biodegradable, and 
biocompatible polymer, with remarkable advantages in clinical use[22]. PMA is a non-toxic 
polymer since it degrades into malic acid after administration, which is an intermediate 
product of carbohydrates metabolism and therefore, non-toxic to cells[27]. In addition, PMA 
contains multiple carboxylic functions that can be used to introduce molecules of interest via 
ester hydrolyzable linkages affording high payload nanoconjugates. 
The copolymer of malic acid carrying pyrazinoic acid was synthesized via a simple 
coupling of the drug on the polymer backbone through an ester cleavable bond, enabling 
degradation of PMA-conjugate into biocompatible metabolites.  
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PMA was first prepared by direct polycondensation of L-malic acid which was carried 
out under reduced pressure without the use of any catalyst[27]. After purification, a high yield 
was achieved, up to 80%, demonstrating that conditions set for this reaction were suitable to 
obtain large batches. Formation of PMA was confirmed by 
1
H NMR analysis through the 
presence of CH2 at 2.9 ppm and CH at 5.4 ppm[28], [29]. The molecular weight of the 
polymer was in the range of 2,000 – 4,000 g/mol. 
Then, PA conjugate was synthesized following a two steps process. Prior to PA 
conjugation onto PMA, a hydrophobic spacer was coupled to the drug through its carboxylic 
function. The use of pyrazinoic acid ester instead of PA provides two additional ester groups 
that can be further hydrolyzed to release the drug from the conjugate. Moreover, in a recent 
study pyrazinoic acid ester analogs have shown a higher efficacy than pyrazinamide[11]. 1,8-
Octanediol was coupled to PA through a classical esterification reaction as shown in Fig. 1. 
Formation of n-octyl pyrazinoic acid (PA:Oct) was confirmed by mass spectrometry through 
m/z fragment at 252.2 and 
1
H NMR by the appearance of the signal at 4.4 ppm attributed to 
COO-CH2- protons (Fig. S1, supporting information). 
 
 
Fig. 1: Synthesis route for pyrazinoic acid ester conjugate (PMA:OctPA). 
The final PA conjugate was obtained as a product of the reaction between PA:Oct and 
PMA using an initial molar feed ratio OH:COOH of 1:3 [Fig. 1]. Conjugation was confirmed 
by 
1
H NMR with the disappearance of the signal at 3.6 ppm corresponding to the CH2 in  of 
hydroxyl group and appearance of a signal at 4.15 ppm attributed to PMA-COO-CH2- protons 
(Fig. S2, supporting information). Additional two-dimensional correlation (COSY) NMR 
spectroscopy experiments corroborated the appearance of the CH2 in  of the ester bond to 
the PMA polymeric chain proving the success of the conjugation. Analysis of the 
1
H NMR 
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spectrum indicates 20 ± 5% of PA:Oct residues coupled to PMA which is satisfactory 
according to the initial feed. This feed composition corresponds to approximately 30 wt% 
pyrazinoic ester residues (~ 16 wt% pyrazinoic acid). 
Nanoconjugate formation 
Nanoconjugates were prepared by a simple process of nanoprecipitation taking 
advantage of the amphiphilic character of PA conjugate which easily self-assembled into 
nanoparticles in aqueous solution. This method is very accurate to produce monodisperse and 
stable nanoparticles, without the addition of surfactant and without the use of toxic 
solvents[30]. DLS analyses showed uniform distributions of size with an average diameter 
around 145nm and a low polydispersity index of 0.13. Mean zeta potential evidenced a 
negatively surface charge of -58mV, consistent with the presence of non-conjugated 
carboxylic residues on the final product which considerably influences the surface charge of 
the resulting nanoconjugate. 
To visualize their morphology and size, nanoconjugates were imaged by TEM with 
negative staining. As shown in Figure 2, a rather homogenous particle size population was 
observed with an average size between 150 and 200nm in diameter, which was consistent 
with DLS data. Moreover, TEM results also evidenced the spherical shape of nanoconjugates 
and the absence of particle aggregation even without the use of stabilizers.  
 
Fig. 2: TEM images with negative staining of NC-PA (scale bar = 200 nm). 
Stability of the nanoconjugates was evaluated at low (4°C) and physiological 
conditions (37°C) over a period of 60 days. Interestingly, NC-PA exhibited excellent colloidal 
stability independently of the storage temperature (Fig. 3). No aggregation was observed and 
the distribution remained narrow over the whole period. 
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The loading rate of pyrazinoic acid, is similar to the feed composition determined for 
PMA:OctPA conjugate since the nanoconjugates are completely formed from the esterified 
poly(malic acid), no additive has been introduced during the nano-precipitation step. 
Therefore, it corresponds to approximately 16 wt% of PA in the final NC-PA. This loading is 
much higher than the one obtained with a simple physical encapsulation of pyrazinamide, the 
esterified drug, in PLGA nanoparticles (around 4wt%)[16]. 
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Fig. 3: Stability tests performed for NC-PA stored at 4 and 37 ºC for 60 days, represented in 
terms of (A) particle size, and (B) PDI. Data represent the mean ± standard deviation (n = 3). 
 
Release study 
Drug release study of the nanoconjugate NC-PA was conducted at 37°C and 
physiological pH in PBS over a period of 10 days. Free PA was also assessed as control, no 
drug degradation was observed in this elapsed time. As shown in Fig. 4, a gradual and 
complete drug release was achieved in almost 6 days from the nanoconjugate. The initial 
release of 10% at 15 min can be attributed to free PA adsorbed on nanoconjugate surface and 
not attached to the polymer. As expected with this kind of drug delivery system, a sustained 
release of pyrazinoic acid with no burst release was observed through the hydrolysis of the 
ester linker between PA and PMA polymer. These drug-controlled release results are 
desirable in overall TB treatment[31], once a unique dose is able to maintain therapeutic 
concentration over a long period and consequently, minimize the drug toxic effects during TB 
therapy, which may help in increasing patient compliance. 
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Fig. 4: In vitro drug release of NC-PA in PBS buffer at 37 ºC. Data represent the mean ± 
standard deviation (n = 3). 
 
In vitro internalization and cytotoxicity studies 
Cytotoxicity of PA nanoconjugates was monitored by MTT assay. NC-PA formulation 
was incubated with macrophages cells in different ranges of increasing concentrations for 
48h. Results (Fig. 5) expressed by means of percentage of cell viability showed that 
nanoconjugates did not exhibit a toxic potential for the majority of concentrations tested (cell 
viability over 70%). Toxicity observed must come exclusively from drugs inherent in the 
constitution of nanoconjugates since previous studies carried out by our team have shown that 
PMA has no toxicity to these cells even at concentrations much higher than those used in this 
work (unpublished work, see Fig. S3, supporting information). Both free drug and PA 
nanoconjugates did not present a toxic potential up to 25µg/ml. Above this concentration, cell 
viability decreased achieving 52 and 40% for free PA and NC-PA, respectively, at 100µg/ml. 
The higher cell viability observed for free PA could be explained by drug physicochemical 
properties. As PA is weakly hydrophobic and highly ionized at physiological pH[9], it is less 
likely that this molecule will cross the cell membrane, causing a lower cell death than PA 
nanoconjugates which are internalized by macrophages as showed below. Similar behavior 
was described by Heifets and co-workers[32], who reported unexpected higher minimum 
inhibitory concentration results for PA than for pyrazinamide against susceptible M. 
tuberculosis strain. The authors associated this finding to inefficient solubilization of PA 
stock solution into water, which leads to the formation of insoluble precipitates after dilution 
in the culture medium. Similarly to this study, the toxic effect of free PA used in this work 
may be underestimated. 
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Fig. 5: Percentage of cell viability over ranges of nanoconjugates concentrations incubated 
with RAW 264.7 macrophages for 48h. Results express the cytotoxic profiles of PA and NC-
PA. Data represent the mean ± standard deviation (n = 3). 
The main triggering factor for tuberculosis management is the administration of anti-
tuberculosis drugs in therapeutic quantities at the target sites i.e. alveolar macrophages. These 
cells are an interesting target in TB treatment, once after inhalation of M. tuberculosis, 
bacteria infect alveolar macrophages and inhibit the phagosome-lysosome fusion, deactivating 
the defensive mechanisms of these cells and using them as a reservoir to replicate and survive 
for a long period[1]. Therefore, in order to propose an efficient nanocarrier to fight against 
TB, it is relevant to assure the capacity of macrophages to uptake nanoparticles. For this 
reason, PA nanoconjugates developed in this work were fluorescently labeled (NC-PAFLU) 
and incubated with macrophages at 10 µg/ml (subtoxic concentration) from 0.5 to 6 hours, at 
37ºC. Internalization of NC-PAFLU by cells was followed by confocal microscopy and 
results are reported on Fig. 6. According to the observations, red fluorescence inside cells 
demonstrated that nanoconjugates were effectively taken up by macrophages over time. 
Besides, these results pointed out that nanoconjugates were located within the cytoplasm 
rather than merely attached on the cell membrane. This ability to spread within cell content 
expressed by NC-PAFLU is particularly interesting in TB therapeutic since nanoconjugates 
can easily face mycobacteria and release drugs directly on the disease target site. 
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Fig. 6: Uptake kinetics of NC-PAFLU incubated with RAW 264.7 macrophages cell line at 
10 µg/ml for different time intervals. (A) Control (cells without treatment), (B) 0.5 h, (C) 1.5 
h, (D) 3 h, (E) 6 h. 
Mean fluorescence inside cells was quantified to investigate the kinetics of the 
nanoconjugate. Data in Fig. 7 express a general profile for NC-PAFLU with increasing 
fluorescence over time to a maximum value after 3h of incubation and then no significant 
change was observed at 6h. At the optimum time point, the internalization of nanoconjugates 
by macrophages was maximal.  
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Fig. 7: Quantification of fluorescence inside cells after incubation with NC-PAFLU at 10 
µg/ml over a range of time points. Data represent the mean ± standard deviation. **: p<0.05 
and ****: p<0.0001. 
 
Finally, NC-PA and PA toxicity were quantitatively expressed by means of IC50. In 
order to induce 50% cell death, doses of 85.42 and 127.4 µg/ml are required for NC-PA and 
PA respectively. According to these results, NC-PA can be considered as a safe 
nanoconjugate since its IC50 is far higher than the concentration necessary for an efficient cell 
uptake (10 µg/ml). This finding corroborates the main goal of this work in proposing safe and 
efficient nanoconjugates able to effectively be taken up by macrophages and improve TB 
treatment. 
Conclusions 
In this work, we demonstrated that PA biodegradable nanoconjugates were successfully 
synthesized as a novel and smart strategy for lung administration. Lateral carboxylic groups 
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of PMA were directly conjugated with PA by a simple esterification reaction, ensuring 
conjugates to self-assemble into nanometric, negatively surface charged and spherical 
nanoconjugates. NC-PA evidenced a sustained drug release, suggesting the ability of this 
nanocarrier to maintain drug concentration over time and consequently, to reduce doses and 
frequency of administration. Allying these findings with the relevant cell culture results, 
which evidenced that nanoconjugates were effectively taken up by cells for 6 hours and did 
not present a cytotoxic profile for a wide range of concentrations, we concluded to the 
discovery of an innovative material with a promising potential in reducing side effects and 
improving TB therapy. These preliminary results encourage to move with these 
nanoconjugates to the perspective of entrapping them into trojan microparticles to enable 
pulmonary administration and delivery on alveolar macrophages. 
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